Cali Reynolds, MD
Allergy & Immunology · Westford, MANPI 1891105268
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AstraZeneca at 53.8% of the total. Reporting peaked in 2023 at $938 and has fallen 65.7% since, to $322 in 2025.
Across 152 payments — averaging $24.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Amgen$432
- Genentech USA, Inc.$322
- GSK$205
- Regeneron Healthcare Solutions, Inc.$142
- Kaleo, Inc.$142
- plus $505 from 11 others
What the payments were for
- Food & beverage$3,780100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 74 | $2,032 |
| Amgen | 27 | $432 |
| Genentech USA, Inc. | 6 | $322 |
| GSK | 11 | $205 |
| Regeneron Healthcare Solutions, Inc. | 6 | $142 |
| Kaleo, Inc. | 6 | $142 |
| Pfizer | 5 | $134 |
| CSL Behring | 2 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $69 |
| Novartis | 3 | $67 |
| Eyevance Pharmaceuticals LLC | 2 | $37 |
| Shire North American Group Inc | 2 | $32 |
| Optinose US, Inc. | 1 | $18 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $15 |
| Pharming Healthcare, Inc. | 1 | $14 |
| Sanofi | 1 | $12 |
| Alk-abello, Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,780 in reported general payments places this provider in the 55th percentile of 114 allergy & immunology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 12 | $33,702 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $4,984 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $570 |
| Azelastine Hcl | 24 | $527 |
| Fluticasone Propionate | 17 | $369 |
| Montelukast Sodium | 12 | $159 |
| Levocetirizine Dihydrochloride | 13 | $152 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Westford
- Sara NarayanWestford$3K
- Wanda PhipatanakulBoston$679K
- Jonathan BayukNorthampton$420K
- Kathleen BuchheitBoston$224K
- Francisco BonillaLeominster$188K
- Aleena BanerjiBoston$133K
- Margo StevensonSturbridge$98K
- Jeffrey GelfandBoston$84K
- Paul MaglioneBoston$66K
- Maria CastellsGardner$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.